LPTX - LEAP THERAPEUTICS, INC.

0.268
-0.024   -9.030%

Share volume: 399,786
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$0.29
-0.02
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 0%
Dept financing 6%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.90%
1 Month
-36.21%
3 Months
-91.24%
6 Months
-88.64%
1 Year
-92.14%
2 Year
-91.49%
Key data
Stock price
$0.27
P/E Ratio 
0.00
DAY RANGE
$0.25 - $0.30
EPS 
-$1.89
52 WEEK RANGE
$0.22 - $4.79
52 WEEK CHANGE
-$91.18
MARKET CAP 
110.164 M
YIELD 
N/A
SHARES OUTSTANDING 
38.264 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
0.38
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$941,976
AVERAGE 30 VOLUME 
$5,495,390
Company detail
CEO: Doug E. Onsi
Region: US
Website: leaptx.com
Employees: 40
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

Recent news
loading